{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:18:29Z","timestamp":1792592309432,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T00:00:00Z","timestamp":1538956800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1038\/s41401-018-0161-0","type":"journal-article","created":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T15:49:27Z","timestamp":1539013767000},"page":"1894-1901","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells"],"prefix":"10.1038","volume":"39","author":[{"given":"Xian-bo","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-mei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-mei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-jin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-bin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,8]]},"reference":[{"key":"161_CR1","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1002\/cncr.29383","volume":"121","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, O\u2019Brien S, Konopleva M, Kantarjian H. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer. 2015;121:2517\u201328.","journal-title":"Cancer"},{"key":"161_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1535-6108(02)00018-1","volume":"1","author":"AA Ferrando","year":"2002","unstructured":"Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1:75\u201387.","journal-title":"Cancer Cell"},{"key":"161_CR3","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1056\/NEJMra052603","volume":"354","author":"CH Pui","year":"2006","unstructured":"Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166\u201378.","journal-title":"N Engl J Med"},{"key":"161_CR4","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1182\/blood-2007-09-112920","volume":"111","author":"A M\u00f6ricke","year":"2008","unstructured":"M\u00f6ricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, D\u00f6rdelmann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477\u201389.","journal-title":"Blood"},{"key":"161_CR5","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/leu.2014.229","volume":"29","author":"DJ DeAngelo","year":"2015","unstructured":"DeAngelo DJ, Stevenson KE, Dahlberg SE, Silverman LB, Couban S, Supko JG, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29:526\u201334.","journal-title":"Leukemia"},{"key":"161_CR6","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3892\/ijo.2014.2525","volume":"45","author":"C Evangelisti","year":"2014","unstructured":"Evangelisti C, Evangelisti C, Chiarini F, Lonetti A, Buontempo F, Bressanin D, et al. Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review). Int J Oncol. 2014;45:909\u201318.","journal-title":"Int J Oncol"},{"key":"161_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/leu.2009.223","volume":"24","author":"WL Zhao","year":"2010","unstructured":"Zhao WL. Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways. Leukemia. 2010;24:13\u201321.","journal-title":"Leukemia"},{"key":"161_CR8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.18632\/oncotarget.477","volume":"3","author":"AM Martelli","year":"2012","unstructured":"Martelli AM, Chiarini F, Evangelisti C, Cappellini A, Buontempo F, Bressanin D, et al. Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget. 2012;3:371\u201394.","journal-title":"Oncotarget"},{"key":"161_CR9","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1242\/jcs.051011","volume":"122","author":"M Laplante","year":"2009","unstructured":"Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009;122:3589\u201394.","journal-title":"J Cell Sci"},{"key":"161_CR10","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1073\/pnas.1320265111","volume":"111","author":"T Hoshii","year":"2014","unstructured":"Hoshii T, Kasada A, Hatakeyama T, Ohtani M, Tadokoro Y, Naka K, et al. Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells. Proc Natl Acad Sci U S A. 2014;111:3805\u201310.","journal-title":"Proc Natl Acad Sci USA"},{"key":"161_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.leukres.2006.08.001","volume":"31","author":"T Ikezoe","year":"2007","unstructured":"Ikezoe T, Nishioka C, Bandobashi K, Yang Y, Kuwayama Y, Adachi Y, et al. Longitudinal inhibition of PI3K\/Akt\/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk Res. 2007;31:673\u201382.","journal-title":"Leuk Res"},{"key":"161_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1745-7254.2008.00767.x","volume":"29","author":"YM Zhao","year":"2008","unstructured":"Zhao YM, Zhou Q, Xu Y, Lai XY, Huang H. Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition. Acta Pharmacol Sin. 2008;29:481\u20138.","journal-title":"Acta Pharmacol Sin"},{"key":"161_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.exphem.2011.01.005","volume":"39","author":"A Batista","year":"2011","unstructured":"Batista A, Barata JT, Raderschall E, Sallan SE, Carlesso N, Nadler LM, et al. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors. Exp Hematol. 2011;39:457\u201372.","journal-title":"Exp Hematol"},{"key":"161_CR14","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3109\/10428194.2013.811579","volume":"55","author":"KN Wu","year":"2014","unstructured":"Wu KN, Zhao YM, He Y, Wang BS, Du KL, Fu S, et al. Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt\/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways. Leuk Lymphoma. 2014;55:668\u201376.","journal-title":"Leuk Lymphoma"},{"key":"161_CR15","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/aps.2015.68","volume":"36","author":"LH Meng","year":"2015","unstructured":"Meng LH, Zheng XF. Toward rapamycin analog (rapalog)-based precision cancer therapy. Acta Pharmacol Sin. 2015;36:1163\u20139.","journal-title":"Acta Pharmacol Sin"},{"key":"161_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1182\/blood-2015-02-629543","volume":"126","author":"TE Witzig","year":"2015","unstructured":"Witzig TE, Reeder C, Han JJ, LaPlant B, Stenson M, Tun HW, et al. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood. 2015;126:328\u201335.","journal-title":"Blood"},{"key":"161_CR17","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1158\/1078-0432.CCR-14-2888","volume":"21","author":"N Daver","year":"2015","unstructured":"Daver N, Boumber Y, Kantarjian H, Ravandi F, Cortes J, Rytting ME, et al. A phase I\/II study of the mTOR inhibitor everolimus in combination with HyperCVAD chemotherapy in patients with relapsed\/refractory acute lymphoblastic leukemia. Clin Cancer Res. 2015;21:2704\u201314.","journal-title":"Clin Cancer Res"},{"key":"161_CR18","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.2741\/3086","volume":"13","author":"M Buxade","year":"2008","unstructured":"Buxade M, Parra-Palau JL, Proud CG. The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases). Front Biosci. 2008;13:5359\u201373.","journal-title":"Front Biosci"},{"key":"161_CR19","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nature02369","volume":"428","author":"HG Wendel","year":"2004","unstructured":"Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 2004;428:332\u20137.","journal-title":"Nature"},{"key":"161_CR20","doi-asserted-by":"publisher","first-page":"6539","DOI":"10.1128\/MCB.24.15.6539-6549.2004","volume":"24","author":"T Ueda","year":"2004","unstructured":"Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol. 2004;24:6539\u201349.","journal-title":"Mol Cell Biol"},{"key":"161_CR21","doi-asserted-by":"crossref","first-page":"56811","DOI":"10.18632\/oncotarget.10796","volume":"7","author":"P Li","year":"2016","unstructured":"Li P, Diab S, Yu M, Adams J, Islam S, Basnet SK, et al. Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells. Oncotarget. 2016;7:56811\u201325.","journal-title":"Oncotarget"},{"key":"161_CR22","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1182\/blood-2016-02-698704","volume":"128","author":"EM Kosciuczuk","year":"2016","unstructured":"Kosciuczuk EM, Saleiro D, Kroczynska B, Beauchamp EM, Eckerdt F, Blyth GT, et al. Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo. Blood. 2016;128:410\u20134.","journal-title":"Blood"},{"key":"161_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/leu.2015.180","volume":"30","author":"H Wu","year":"2016","unstructured":"Wu H, Hu C, Wang A, Weisberg EL, Chen Y, Yun CH, et al. Discovery of a BTK\/MNK dual inhibitor for lymphoma and leukemia. Leukemia. 2016;30:173\u201381.","journal-title":"Leukemia"},{"key":"161_CR24","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O\u2019Reilly","year":"2006","unstructured":"O\u2019Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500\u20138.","journal-title":"Cancer Res"},{"key":"161_CR25","first-page":"3065","volume":"118","author":"A Carracedo","year":"2008","unstructured":"Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008;118:3065\u201374.","journal-title":"J Clin Invest"},{"key":"161_CR26","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.4161\/cbt.7.12.6944","volume":"7","author":"X Wang","year":"2008","unstructured":"Wang X, Hawk N, Yue P, Kauh J, Ramalingam SS, Fu H, et al. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors\u2019 anticancer efficacy. Cancer Biol Ther. 2008;7:1952\u20138.","journal-title":"Cancer Biol Ther"},{"key":"161_CR27","doi-asserted-by":"publisher","first-page":"37407","DOI":"10.18632\/oncotarget.9822","volume":"7","author":"D Brunen","year":"2016","unstructured":"Brunen D, Garc\u00eda-Barchino MJ, Malani D, Jagalur Basheer N, Lieftink C, Beijersbergen RL, et al. Intrinsic resistance to PIM kinase inhibition in AML through p38\u03b1-mediated feedback activation of mTOR signaling. Oncotarget. 2016;7:37407\u201319.","journal-title":"Oncotarget"},{"key":"161_CR28","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.chembiol.2014.01.011","volume":"21","author":"S Diab","year":"2014","unstructured":"Diab S, Kumarasiri M, Yu M, Teo T, Proud C, Milne R, et al. MAP kinase-interacting kinases-emerging targets against cancer. Chem Biol. 2014;21:441\u201352.","journal-title":"Chem Biol"},{"key":"161_CR29","doi-asserted-by":"publisher","first-page":"e0161158","DOI":"10.1371\/journal.pone.0161158","volume":"11","author":"S Gusscott","year":"2016","unstructured":"Gusscott S, Jenkins CE, Lam SH, Giambra V, Pollak M, Weng AP. IGF1R derived PI3K\/AKT signaling maintains growth in a subset of human T-cell acute lymphoblastic leukemias. PLoS One. 2016;11:e0161158.","journal-title":"PLoS ONE"},{"key":"161_CR30","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1084\/jem.20110121","volume":"208","author":"H Medyouf","year":"2011","unstructured":"Medyouf H, Gusscott S, Wang H, Tseng JC, Wai C, Nemirovsky O, et al. High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J Exp Med. 2011;208:1809\u201322.","journal-title":"J Exp Med"},{"key":"161_CR31","doi-asserted-by":"publisher","first-page":"118","DOI":"10.18632\/oncotarget.453","volume":"3","author":"J Hou","year":"2012","unstructured":"Hou J, Lam F, Proud C, Wang S. Targeting Mnks for cancer therapy. Oncotarget. 2012;3:118\u201331.","journal-title":"Oncotarget"},{"key":"161_CR32","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/bjc.2013.505","volume":"109","author":"E Seront","year":"2013","unstructured":"Seront E, Pinto A, Bouzin C, Bertrand L, Machiels JP, Feron O. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K\/Akt activation. Br J Cancer. 2013;109:1586\u201392.","journal-title":"Br J Cancer"},{"key":"161_CR33","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2014.123","volume":"28","author":"J Bertacchini","year":"2014","unstructured":"Bertacchini J, Guida M, Accordi B, Mediani L, Martelli AM, Barozzi P, et al. Feedbacks and adaptive capabilities of the PI3K\/Akt\/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis. Leukemia. 2014;28:2197\u2013205.","journal-title":"Leukemia"},{"key":"161_CR34","doi-asserted-by":"publisher","first-page":"e80070","DOI":"10.1371\/journal.pone.0080070","volume":"8","author":"S Badura","year":"2013","unstructured":"Badura S, Tesanovic T, Pfeifer H, Wystub S, Nijmeijer BA, Liebermann M, et al. Differential effects of selective inhibitors targeting the PI3K\/AKT\/mTOR pathway in acute lymphoblastic leukemia. PLoS One. 2013;8:e80070.","journal-title":"PLoS ONE"},{"key":"161_CR35","doi-asserted-by":"publisher","first-page":"7405","DOI":"10.1128\/MCB.00760-07","volume":"27","author":"X Wang","year":"2007","unstructured":"Wang X, Yue P, Chan CB, Ye K, Ueda T, Watanabe-Fukunaga R, et al. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol. 2007;27:7405\u201313.","journal-title":"Mol Cell Biol"},{"key":"161_CR36","doi-asserted-by":"crossref","first-page":"27787","DOI":"10.18632\/oncotarget.8497","volume":"7","author":"Q Wen","year":"2016","unstructured":"Wen Q, Wang WY, Luo JD, Chu SZ, Chen LJ, Xu LN, et al. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway. Oncotarget. 2016;7:27787\u2013801.","journal-title":"Oncotarget"},{"key":"161_CR37","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1111\/j.1349-7006.2012.02359.x","volume":"103","author":"M Yunokawa","year":"2012","unstructured":"Yunokawa M, Koizumi F, Kitamura Y, Katanasaka Y, Okamoto N, Kodaira M, et al. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. Cancer Sci. 2012;103:1665\u201371.","journal-title":"Cancer Sci"},{"key":"161_CR38","doi-asserted-by":"publisher","first-page":"e0131400","DOI":"10.1371\/journal.pone.0131400","volume":"10","author":"EY Leung","year":"2015","unstructured":"Leung EY, Askarian-Amiri M, Finlay GJ, Rewcastle GW, Baguley BC. Potentiation of growth inhibitory responses of the mTOR inhibitor everolimus by dual mTORC1\/2 inhibitors in cultured breast cancer cell lines. PLoS One. 2015;10:e0131400.","journal-title":"PLoS ONE"},{"key":"161_CR39","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1016\/j.febslet.2013.06.045","volume":"587","author":"RL Stead","year":"2013","unstructured":"Stead RL, Proud CG. Rapamycin enhances eIF4E phosphorylation by activating MAP kinase-interacting kinase 2a (Mnk2a). FEBS Lett. 2013;587:2623\u20138.","journal-title":"FEBS Lett"},{"key":"161_CR40","doi-asserted-by":"publisher","first-page":"8442","DOI":"10.18632\/oncotarget.2319","volume":"5","author":"F Eckerdt","year":"2014","unstructured":"Eckerdt F, Beauchamp E, Bell J, Iqbal A, Su B, Fukunaga R, et al. Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells. Oncotarget. 2014;5:8442\u201351.","journal-title":"Oncotarget"},{"key":"161_CR41","doi-asserted-by":"publisher","first-page":"13984","DOI":"10.1073\/pnas.1008136107","volume":"107","author":"T Ueda","year":"2010","unstructured":"Ueda T, Sasaki M, Elia AJ, Chio II, Hamada K, Fukunaga R, et al. Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Natl Acad Sci U S A. 2010;107:13984\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"key":"161_CR42","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1126\/science.1102160","volume":"306","author":"AP Weng","year":"2004","unstructured":"Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306:269\u201371.","journal-title":"Science"},{"key":"161_CR43","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1182\/blood-2016-09-692582","volume":"129","author":"M Sanchez-Martin","year":"2017","unstructured":"Sanchez-Martin M, Ferrando A. The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia. Blood. 2017;129:1124\u201333.","journal-title":"Blood"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41401-018-0161-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-018-0161-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-018-0161-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:01:26Z","timestamp":1684616486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-018-0161-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,8]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["161"],"URL":"https:\/\/doi.org\/10.1038\/s41401-018-0161-0","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,8]]},"assertion":[{"value":"9 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}